We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of Florbetapir (18F) in Japanese Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01660815
Recruitment Status : Completed
First Posted : August 9, 2012
Results First Posted : September 19, 2013
Last Update Posted : September 19, 2013
Eli Lilly and Company
Information provided by (Responsible Party):
Avid Radiopharmaceuticals

Brief Summary:
This study will determine how florbetapir (18F) (18F-AV-45) radioactivity is distributed throughout the body of Japanese subjects.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: florbetapir (18F) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: PET Whole Body Biodistribution Using Florbetapir (18F)
Study Start Date : August 2012
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Healthy Volunteers
Cognitively normal, healthy volunteers at least 45 years of age.
Drug: florbetapir (18F)
IV injection, 370 MBq (10mCi), single dose
Other Names:
  • 18F-AV-45
  • Amyvid
  • Florbetapir F 18

Primary Outcome Measures :
  1. Whole Body Radiation Dosimetry [ Time Frame: 0-360 minutes ]
    Radiation dose values (millisieverts/megabecquerel [mSv/MBq]) were calculated for target organs, including the adrenals, brain, breasts, gall bladder wall, heart wall, kidneys, lower large intestine wall, liver, lungs, muscle, ovaries, osteogenic cells, pancreas, red marrow, skin, small intestine, spleen, stomach wall, testes, thymus, thyroid, total body, upper large intestine wall, urinary bladder wall, and uterus.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Are Japanese cognitively normal healthy males or females at least 45 years of age;
  2. Give informed consent; and
  3. Are able to lie still on the imaging table for periods up to one hour.

Exclusion Criteria:

  1. Have had radiation exposure (PET, SPECT or CT scans) for experimental purposes within the last year;
  2. Are claustrophobic or otherwise unable to tolerate the imaging procedure;
  3. Have medical conditions or surgical history that would confound evaluation of dosimetry (e.g., liver disease, colectomy etc.);
  4. Have current clinically significant cardiovascular disease. Clinically significant cardiovascular disease usually includes one or more of the following:

    1. cardiac surgery or myocardial infarction within the last 6 months;
    2. unstable angina;
    3. coronary artery disease that required a change in medication within the last 3 months;
    4. decompensated congestive heart failure;
    5. significant cardiac arrhythmia or conduction disturbance, particularly those resulting in atrial or ventricular fibrillation, or causing syncope, near syncope, or other alterations in mental status;
    6. severe mitral or aortic valvular disease;
    7. uncontrolled high blood pressure;
    8. congenital heart disease;
    9. clinically significant abnormal result on ECG, including but not limited to QTc>450 msec; Before enrolling a patient with any evidence of the above conditions, the investigator must contact the sponsor;
  5. Have current clinically significant medical comorbidities, as indicated by history, physical exam, or laboratory evaluations that might pose a potential safety risk, interfere with the absorption or metabolism of the study medication or limit interpretation of the trial results. These include but are not limited to clinically significant hepatic, renal, pulmonary, metabolic or endocrine disease, cancer;
  6. Have a history of drug or alcohol abuse within the last year, or prior prolonged history of abuse;
  7. Have a history of epilepsy or convulsions, except for febrile convulsions during childhood;
  8. Have clinically significant infectious disease, including AIDS or HIV infection or previous positive test for hepatitis B, hepatitis C, HIV-1, or HIV-2;
  9. Have had a radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session;
  10. Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception. Females of childbearing potential must not be pregnant (negative serum β-HCG at the time of screening) or breastfeeding at screening. Females must agree to avoid becoming pregnant, and must agree to refrain from sexual activity or to use reliable methods of contraception such as prescribed birth control or IUD for 24 hours following administration of florbetapir (18F);
  11. Have a history of severe drug allergy or hypersensitivity;
  12. Received an investigational medication within the last 30 days or who have participated in a clinical trial with any experimental medication in the last 30 days.

    Additionally, the time between the last dose of the previous experimental medication and enrollment (completion of screening assessments) must be at least equal to 5 times the terminal half-life of the previous experimental medication;

  13. Have known hypersensitivity to alcohol; and
  14. In the opinion of the investigator, are otherwise unsuitable for a study of this type.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01660815

Layout table for location information
Research Site
Kobe, Japan
Sponsors and Collaborators
Avid Radiopharmaceuticals
Eli Lilly and Company
Layout table for investigator information
Study Director: Chief Medical Officer Avid Radiopharmaceuticals
Layout table for additonal information
Responsible Party: Avid Radiopharmaceuticals
ClinicalTrials.gov Identifier: NCT01660815    
Other Study ID Numbers: 18F-AV-45-J02
I6E-AV-AVBA ( Other Identifier: Eli Lilly Japan )
First Posted: August 9, 2012    Key Record Dates
Results First Posted: September 19, 2013
Last Update Posted: September 19, 2013
Last Verified: July 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders